3-(5-Benzyloxy-1H-indol-3-yl)-1-benzyloxymethyl-4-[5-benzyloxy-1-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione | 220873-41-6

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 3-(5-Benzyloxy-1H-indol-3-yl)-1-benzyloxymethyl-4-[5-benzyloxy-1-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
• CAS: 220873-41-6
• 化学式: C₇₆H₆₇N₃O₁₀
• 分子量: 1182.38
• InChiKey: HFAPOBBUEMPYFV-UYCYBHFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.6
• 重原子数：
  89.0
• 可旋转键数：
  26.0
• 环数：
  13.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  131.94
• 氢给体数：
  1.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  3-(5-Benzyloxy-1H-indol-3-yl)-1-benzyloxymethyl-4-[5-benzyloxy-1-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione 在 palladium(II) trifluoroacetate 、 溶剂黄146 作用下， 生成
  参考文献：
  名称：

  Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110

  摘要：

  All four "symmetrical" regioisomers of ED-110, an indolocarbazole derivative having potent activity against human topoisomerase I (Topo I) were synthesized. The isomer containing hydroxyl groups in the 3- and 9-positions was approximately ten-fold more active against Topo I, and 5- to 35-fold more active against human solid tumor cell lines in vitro, relative to ED-110. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00710-0
• 作为产物：
  描述：

  N-benzyloxymethyl-3,4-dibromomaleimide 在 甲基碘化镁 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 生成 3-(5-Benzyloxy-1H-indol-3-yl)-1-benzyloxymethyl-4-[5-benzyloxy-1-((2R,3R,4S,5R,6R)-3,4,5-tris-benzyloxy-6-benzyloxymethyl-tetrahydro-pyran-2-yl)-1H-indol-3-yl]-pyrrole-2,5-dione
  参考文献：
  名称：

  Indolocarbazole poisons of human topoisomerase I: Regioisomeric analogues of ED-110

  摘要：

  All four "symmetrical" regioisomers of ED-110, an indolocarbazole derivative having potent activity against human topoisomerase I (Topo I) were synthesized. The isomer containing hydroxyl groups in the 3- and 9-positions was approximately ten-fold more active against Topo I, and 5- to 35-fold more active against human solid tumor cell lines in vitro, relative to ED-110. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00710-0